Behringwerke Aktiengesellschaft

Dade Behring Marburg Gmbh

Hans Kupper

Burkhard Enders

Erika Hundt

Bernhard Knapp

Stefan Knapp

Gerd Zettlmeissl

Robert Ziegelmaier

Mathias Fibi

Bernard Knapp

The present invention relates to the identification of Toxoplasma gondii antigens and the preparation thereof by genetic engineering. A cDNA expression gene bank of this parasite was prepared. Recombinant clones which are of diagnostic interest were identified using a high-titer rabbit anti-Toxoplasma gondii serum, and isolated.

Toxoplasma gondii antigens, the preparation thereof and the use thereof

The invention relates to muteins of human erythropoietin (EPO) in the carboxyl terminal region which are prepared by means of recombinant DNA techniques. These mutants have advantageous properties in comparison with human wild-type EPO.

Muteins of human erythropoietin, the preparation thereof and the use

Protective Plasmodium falciparum hybrid proteins which contain part-sequences of the malaria antigens HRPII and SERP, the preparation and use thereof. The invention relates to hybrid proteins composed of part-sequences of the malaria antigens HRPII and SERP. The HRPII sequence has already proven protective in the monkey model (EP-A2-0 315 085), where a C-terminal region of 189 amino acids has been used in the present invention in the same way as in the preceding protection experiment. SERP was identified with the aid of an antiserum against a protective protein band (EP-A1-0 283 882); the part-sequence used (amino acids (AA) 631-892 or 630-764) contains at least two T-cell epitopes (Roussilhon et al. (1990), Immunol. Letters 25, 149-154). In preferred embodiments, further T-cell epitope-containing regions of other P. falciparum proteins such as merozoite surface antigen I (MSA I or else '195 kd antigen'), amino acids from 100 to 300, are incorporated (Crisanti et al. (1988), Science 240, 324-326). The property common to all the hybrid components is that they represent highly conserved peptide sequences. Protection against a malaria infection is generated by immunization with abovementioned hybrid proteins.

Protective Plasmodium falciparum hybrid proteins which contain

Recombinant histidine-rich protein of Plasmodium falciparum, its preparation and use. It was possible, by screening two different Plasmodium falciparum cDNA gene banks with an antiserum against a 41 kD protein and by cross-hybridization with the insert DNA of a clone obtained therewith, to isolate a gene which codes for a Histidine-Alanine-rich protein (HRP-II). This protein protects aotus monkeys from infection with P. falciparum and is thus a suitable constituent of a malaria vaccine.

Plasmodium falciparum vaccine comprising a recombinant histidine-rich

The invention relates to malaria-specific DNA sequences, to the expression products thereof, and to the use thereof. A combination of three of the expression proteins whose DNA sequences were isolated by screening a lambda gt11 gene bank with a monospecific antiserum against the protective 41kD antigen bend from P. falciparum protects Aotus monkeys completely from a P. falciparum infection in model experiments.

Growing community of inventors

Marburg, Germany

Hans Kupper